Avricore Health Inc. (AVCRF)
OTC PINK OTC PINK Primary 
HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Results to Millions in UK
VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) today announced its successful integration of HealthTab™ the Company's cloud-connected, pharmacy-based platform for testing and health data management, with Patients Know Best (PKB), the UK's leading patient personal health record (PHR). The new partnership enables a seamless connection between real-time diagnostic results from pharmacy point-of-care testing and PKB's PHR platform, enhancing data accessibility for patients and healthcare providers alike.
Avricore Health Refocuses Strategy to Unlock Growth Potential
VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSX-V: AVCR) ("Avricore" or the "Company"), a leader in pharmacy-based point-of-care testing solutions, today announces a strategic shift to increase its focus on the rapidly expanding UK healthcare market and begin concluding its Canadian pharmacy partnership with Shoppers Drug Mart. This shift in market development builds on the UCL Partners announcement of its rapid cholesterol initiative in community pharmacies in North East London.
Avricore Health Recognized in Deloitte's 2024 Technology Fast 50™ Companies to Watch
VANCOUVER, British Columbia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSX-V: AVCR), a leader in pharmacy-based health technology solutions, proudly announces its placement in Deloitte Canada's 2024 Technology Fast 50™ Companies-to-Watch category, securing the 8th position with an impressive growth rate of 2738%. This award acknowledges Avricore's pioneering work in real-time data and health testing through its platform, HealthTab™, which empowers pharmacies to support patient health outcomes effectively.
Avricore Health passes major milestone as it moves into profitability
Avricore Health (TSX-V:AVCR, OTC:AVCRF) passed a significant milestone in its commercial journey as it reported its first-ever profit in the three months ended March 31, posting $168,537 of comprehensive income. Revenue for the period increased by 79% year over year to $1.12 million, while gross profit rose by 130% to $484,791.
